Verastem, with Phase 3 Results, to Request FDA Approve Oral Duvelisib to Treat Advanced CLL and SLL

[wmay13241]

Verastem’s duvelisib was seen to outperform Arzerra (ofatumumab) in a Phase 3 trial of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), the company announced.

The oral therapy nearly halved the risk of disease progression or death, and held patients progression-free for a median of 13.3 months. This was 3.4 months longer than in patients treated with Arzerra.

Source: phx.corporate-ir.net/phoeni...